Radiological Associates of Sacramento

Clinical Trials
(RTOG 0415)

RTOG 0415 Prostate
A Phase III Randomized Study of Hypofractionated 3-D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer

General Information

Purpose

The goal of this study is to determine if radiation therapy given for favorable-risk prostate cancer patients given in fewer fractions (28 fractions over 5.6 weeks) is as effective as standard radiation (41 fractions over 8.2 weeks).

Protocol Number

RTOG 0415 Prostate

Eligibility Criteria

Biopsy proven adenocarcinoma of the prostate within 180 days of randomization.
Gleason score between 2 - 6.
Stage T1-T2c.
PSA less than 10 mg/ml.
No prior malignancies unless disease free for 5 years.
No previous on concurrent chemotherapy for prostate cancer.
No hormonal therapy.

Treatment Plan

Patients agreeing to participate will be assigned at random to one of the following treatment regimens:

1. A Standard daily dose of three-dimensional (3-D) or Intensity Modulated Radiation Therapy (IMRT).. The radiation will be given once daily, 5 days a week, Monday through Friday, for a total of 41 treatments. Each radiation treatment will take 15-30 minutes.

2. A higher daily dose of 3-D radiation or IMRT. The radiation therapy will be given once daily, 5 days a week, Monday through Friday, for a total of 28 treatments. Each radiation treatment will take 15-30 minutes.

Contact Information

For additional information regarding this study, contact the Clinical Research Associates at Radiological Associates, Radiation Oncology Center, Sacramento (916) 454-6699 X80382 or 80383.

Date Updated

06/19/2007

RTOG 0415

Clinical Trials(RTOG 0415)

General Information

Clinical Trials
(RTOG 0415)